Recruiting

Observational Study

Sponsor:

Mayo Clinic

Code:

NCT07805083

Conditions

Hematopoietic and Lymphatic System Neoplasm

Malignant Solid Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Educational Cancer Intervention

ICF Text Version 1

ICF Text Version 2

ICF Video Version 1

ICF Video Version 2

Study Details

Brief summary:

The goal of this clinical trial is to examine perceptions of virtual human communicators and cancer research recruitment messages. This study will also examine how different informed consent approaches influence decisions to participate in research.

Conditions

Hematopoietic and Lymphatic System Neoplasm

Malignant Solid Neoplasm

Study ID

NCT07805083

Start date

Jul 21, 2026

Status verified date

Sep, 2026

Completion date

Jul 20, 2029

Anticipated

Primary completion date

Jul 20, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Able to speak, read, or understand English sufficiently to provide informed consent
  • 18 years of age or older
  • White or Black
  • Living in the United States

Exclusion Criteria:

  • Unable to speak, read, or understand English sufficiently to provide informed consent
  • Inability on the part of the patient to understand the informed consent or be compliant with the protocol

Study Design

Enrollment

600 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Health Services Research

Interventions and Outcome Measures

Arms

experimental: Arm I - ICF Text Version 1

Patients receive a standard of care-based informed consent form. Patients then complete an educational cancer messaging intervention where patients view images of virtual humans, view cancer recruitment study message frames and view images of hospital/institutional single-endorsement and multi-endorsement cancer study recruitment advertisements and rate them for credibility.

experimental: Arm II - ICF Text Version 2

Patients receive a modified community-enhanced language text-based informed consent form. Patients then complete an educational cancer messaging intervention where patients view images of virtual humans, view cancer recruitment study message frames and view images of hospital/institutional single-endorsement and multi-endorsement cancer study recruitment advertisements and rate them for credibility.

experimental: Arm III - ICF Video Version 1

Patients receive a video-based community-enhanced informed consent form delivered by a virtual human educator (Physician A). The virtual human explains the informed consent form content using the language from Arm II. Patients then complete an educational cancer messaging intervention where patients view images of virtual humans, view cancer recruitment study message frames and view images of hospital/institutional single-endorsement and multi-endorsement cancer study recruitment advertisements and rate them for credibility.

experimental: Arm IV - ICF Video Version 2

Patients receive a video-based community-enhanced informed consent form delivered by a virtual human educator (Physician B). The virtual human explains the informed consent form content using the language from Arm II. Patients then complete an educational cancer messaging intervention where patients view images of virtual humans, view cancer recruitment study message frames and view images of hospital/institutional single-endorsement and multi-endorsement cancer study recruitment advertisements and rate them for credibility.

experimental: Arm V - ICF Video Version 3

Patients receive a video-based community-enhanced informed consent form delivered by a virtual human educator (Community Member A). The virtual human explains the informed consent form content using the language from Arm II. Patients then complete an educational cancer messaging intervention where patients view images of virtual humans, view cancer recruitment study message frames and view images of hospital/institutional single-endorsement and multi-endorsement cancer study recruitment advertisements and rate them for credibility.

experimental: Arm VI - ICF Video Version 4

Patients receive a video-based community-enhanced informed consent form delivered by a virtual human educator (Community Member B). The virtual human explains the informed consent form content using the language from Arm II. Patients then complete an educational cancer messaging intervention where patients view images of virtual humans, view cancer recruitment study message frames and view images of hospital/institutional single-endorsement and multi-endorsement cancer study recruitment advertisements and rate them for credibility.

Interventions

Educational Cancer Intervention

Participants will view informed consent messaging presented in different formats

ICF Text Version 1

Receive a text-based informed consent form

ICF Text Version 2

Receive an adapted text-based informed consent form

ICF Video Version 1

Receive a video-based informed consent form delivered by virtual human #1

ICF Video Version 2

Receive a video-based informed consent form delivered by virtual human #2

ICF Video Version 3

Receive a video-based informed consent form delivered by virtual human #3

ICF Video Version 4

Receive a video-based informed consent form delivered by virtual human #4

Survey Administration

Ancillary studies

Primary outcome measure

  • Self-efficacy (Aim 1) [ Time Frame: Baseline (immediately following intervention) ]
  • Trustworthiness (Aim 2) [ Time Frame: Baseline (immediately following intervention) ]

Central Contacts and Locations

Central contacts

Locations

Mayo Clinic in Florida

Recruiting

Jacksonville, Florida, United States, 32224-9980

Contacts

Principal Investigator:

Janice L. Krieger, PhD

More Information

Sponsor

Mayo Clinic

Last update posted

Sep 8, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2026-09-08.